In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The price of Vir Biotechnology Inc (NASDAQ: VIR) closed at $4.44 in the last session, down -2.84% from day before closing price of $4.57. In other words, the price has decreased by -$2.84 from its previous closing price. On the day, 0.99 million shares were traded. VIR stock price reached its highest trading level at $4.49 during the session, while it also had its lowest trading level at $4.33.
Ratios:
We take a closer look at VIR’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 7.01 and its Current Ratio is at 7.01. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, JP Morgan on January 29, 2024, Downgraded its rating to Neutral and sets its target price to $9 from $23 previously.
On September 08, 2023, BofA Securities Downgraded its rating to Neutral which previously was Buy and also lowered its target price recommendation from $23 to $14.
JP Morgan Upgraded its Neutral to Overweight on March 06, 2023, whereas the target price for the stock was revised from $35 to $34.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Aug 01 ’25 when SATO VICKI L sold 22,000 shares for $4.99 per share. The transaction valued at 109,699 led to the insider holds 1,276,391 shares of the business.
Eisner Mark sold 6,796 shares of VIR for $37,162 on Jul 15 ’25. The EVP and Chief Medical Officer now owns 108,204 shares after completing the transaction at $5.47 per share. On Jul 17 ’25, another insider, Eisner Mark, who serves as the EVP and Chief Medical Officer of the company, sold 3,586 shares for $5.47 each. As a result, the insider received 19,629 and left with 104,618 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, VIR now has a Market Capitalization of 616787072 and an Enterprise Value of 112999928. For the stock, the TTM Price-to-Sale (P/S) ratio is 32.46 while its Price-to-Book (P/B) ratio in mrq is 0.65. Its current Enterprise Value per Revenue stands at 5.947 whereas that against EBITDA is -0.204.
Stock Price History:
The Beta on a monthly basis for VIR is 1.27, which has changed by -0.48491877 over the last 52 weeks, in comparison to a change of 0.16461086 over the same period for the S&P500. Over the past 52 weeks, VIR has reached a high of $14.45, while it has fallen to a 52-week low of $4.16. The 50-Day Moving Average of the stock is -15.12%, while the 200-Day Moving Average is calculated to be -36.66%.
Shares Statistics:
According to the various share statistics, VIR traded on average about 1.22M shares per day over the past 3-months and 1200750 shares per day over the past 10 days. A total of 138.89M shares are outstanding, with a floating share count of 89.58M. Insiders hold about 35.52% of the company’s shares, while institutions hold 55.33% stake in the company. Shares short for VIR as of 1753920000 were 11139128 with a Short Ratio of 9.15, compared to 1751241600 on 11221883. Therefore, it implies a Short% of Shares Outstanding of 11139128 and a Short% of Float of 12.920000000000002.
